Literature DB >> 20660053

Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism.

Andrew C Kontak1, Zhongyun Wang, Debbie Arbique, Beverley Adams-Huet, Richard J Auchus, Shawna D Nesbitt, Ronald G Victor, Wanpen Vongpatanasin.   

Abstract

CONTEXT: Aldosterone has been shown to exert a central sympathoexcitatory action in multiple animal models, but evidence in humans is still lacking.
OBJECTIVES: Our objective was to determine whether hyperaldosteronism causes reversible sympathetic activation in humans.
METHODS: We performed a cross-sectional comparison of muscle sympathetic nerve activity (SNA, intraneural microelectrodes) in 14 hypertensive patients with biochemically proven primary aldosteronism (PA) with 20 patients with essential hypertension (EH) and 18 age-matched normotensive (NT) controls. Seven patients with aldosterone-producing adenoma (APA) were restudied 1 month after unilateral adrenalectomy.
RESULTS: Mean blood pressure values in patients with PA and EH and NT controls was 145 ± 4/88 ± 2, 150 ± 4/90 ± 2, and 119 ± 2/76 ± 2 mm Hg, respectively. The major new findings are 2-fold: 1) baseline SNA was significantly higher in the PA than the NT group (40 ± 3 vs. 30 ± 2 bursts/min, P = 0.014) but similar to the EH group (41 ± 3 bursts/min) and 2) after unilateral adrenalectomy for APA, SNA decreased significantly from 38 ± 5 to 27 ± 4 bursts/min (P = 0.01), plasma aldosterone levels fell from 72.4 ± 20.3 to 11.4 ± 2.3 ng/dl (P < 0.01), and blood pressure decreased from 155 ± 8/94 ± 3 to 117 ± 4/77 ± 2 mm Hg (P < 0.01).
CONCLUSION: These data provide the first evidence in humans that APA is accompanied by reversible sympathetic overactivity, which may contribute to the accelerated hypertensive target organ disease in this condition.

Entities:  

Mesh:

Year:  2010        PMID: 20660053      PMCID: PMC3050103          DOI: 10.1210/jc.2010-0823

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

Review 1.  Brain mineralocorticoid receptors and centrally regulated functions.

Authors:  E R de Kloet; S A Van Acker; R M Sibug; M S Oitzl; O C Meijer; K Rahmouni; W de Jong
Journal:  Kidney Int       Date:  2000-04       Impact factor: 10.612

2.  Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation.

Authors:  Kazuko Masuo; Hideki Kawaguchi; Hiroshi Mikami; Toshio Ogihara; Michael L Tuck
Journal:  Hypertension       Date:  2003-09-02       Impact factor: 10.190

Review 3.  Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves.

Authors:  A B Vallbo; K E Hagbarth; H E Torebjörk; B G Wallin
Journal:  Physiol Rev       Date:  1979-10       Impact factor: 37.312

4.  Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure.

Authors:  J Francis; R M Weiss; S G Wei; A K Johnson; T G Beltz; K Zimmerman; R B Felder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-11       Impact factor: 4.733

5.  Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension.

Authors:  D Walter Wray; Mark A Supiano
Journal:  Hypertension       Date:  2010-04-05       Impact factor: 10.190

6.  Brain sodium channels and ouabainlike compounds mediate central aldosterone-induced hypertension.

Authors:  Hao Wang; Bing S Huang; Frans H H Leenen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-08-21       Impact factor: 4.733

Review 7.  Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride.

Authors:  G Jürgens; N A Graudal
Journal:  Cochrane Database Syst Rev       Date:  2004

8.  The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health.

Authors:  Ronald G Victor; Robert W Haley; DuWayne L Willett; Ronald M Peshock; Patrice C Vaeth; David Leonard; Mujeeb Basit; Richard S Cooper; Vincent G Iannacchione; Wendy A Visscher; Jennifer M Staab; Helen H Hobbs
Journal:  Am J Cardiol       Date:  2004-06-15       Impact factor: 2.778

9.  Mineralocorticoids act centrally to regulate blood-borne tumor necrosis factor-alpha in normal rats.

Authors:  Joseph Francis; Terry Beltz; Alan Kim Johnson; Robert B Felder
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-12       Impact factor: 3.619

10.  Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins.

Authors:  M Uhr; F Holsboer; M B Müller
Journal:  J Neuroendocrinol       Date:  2002-09       Impact factor: 3.627

View more
  32 in total

1.  Classics in Cardiovascular Endocrinology: Aldosterone Action Beyond Electrolytes.

Authors:  Richard J Auchus
Journal:  Endocrinology       Date:  2015-12-23       Impact factor: 4.736

2.  Asian women have attenuated sympathetic activation but enhanced renal-adrenal responses during pregnancy compared to Caucasian women.

Authors:  Yoshiyuki Okada; Stuart A Best; Sara S Jarvis; Shigeki Shibata; Rosemary S Parker; Brian M Casey; Benjamin D Levine; Qi Fu
Journal:  J Physiol       Date:  2015-01-26       Impact factor: 5.182

3.  Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.

Authors:  Prafull Raheja; Angela Price; Zhongyun Wang; Debbie Arbique; Beverley Adams-Huet; Richard J Auchus; Wanpen Vongpatanasin
Journal:  Hypertension       Date:  2012-06-25       Impact factor: 10.190

Review 4.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

5.  Adrenal Tissue-Specific Deletion of TASK Channels Causes Aldosterone-Driven Angiotensin II-Independent Hypertension.

Authors:  Nick A Guagliardo; Junlan Yao; Eric J Stipes; Sylvia Cechova; Thu H Le; Douglas A Bayliss; David T Breault; Paula Q Barrett
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

Review 6.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

7.  Global- and renal-specific sympathoinhibition in aldosterone hypertension.

Authors:  Thomas E Lohmeier; Boshen Liu; Drew A Hildebrandt; Adam W Cates; Dimitrios Georgakopoulos; Eric D Irwin
Journal:  Hypertension       Date:  2015-04-20       Impact factor: 10.190

Review 8.  Central regulation of blood pressure by the mineralocorticoid receptor.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

Review 9.  The sympathetic nervous system alterations in human hypertension.

Authors:  Guido Grassi; Allyn Mark; Murray Esler
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

Review 10.  The ubiquitous mineralocorticoid receptor: clinical implications.

Authors:  Urseline A Hawkins; Elise P Gomez-Sanchez; Clara M Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.